$MOH

Molina Healthcare Inc (MOH) Stock Forecasts

Argus raised its target price for Molina Healthcare Inc (MOH) to $205.00. The company provides Medicaid-focused healthcare plans for low-income individuals and families.

Original reporting
Published Oct 7, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 12:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MOH
Bullish
medium confidence
Mentioned
$MOH
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$MOHBullishMed
01

Why it matters

A higher target price can attract investors, potentially lifting the stock.

02

Market read

Analyst upgrade may prompt short‑term buying interest in MOH.

03

What to watch

Potential regulatory changes or enrollment shifts could offset upside.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

The article reports a new analyst target price for Molina Healthcare, indicating a revised outlook.

Company-level read

Ticker impact

$MOHBullishMedium confidence
Context

Analyst raises target price to $205.00 for Molina Healthcare.

Expected impact

likely upward pressure as market prices in higher target.

Evidence & confidence

Target raise reflects improved expectations for earnings and growth.

Market effects

Positive signal for health‑insurance sector.

US market may see modest buying in related stocks.

Limited to US investors; minimal global effect.

Counterpoint

Target may be overly optimistic if underlying earnings miss expectations.

Key entities

  • Molina Healthcare Inc

    US‑listed health‑insurance provider (ticker MOH).

Related articles

$CNCHigh

ACA fraud crackdown threatens health insurer profits in 2026

Vice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.

$MOHMed

Molina to End Its Medicare Advantage Drug Plans on December 31. The Decision Was Announced in February. The Letter Telling Members Arrives in October

Molina Healthcare (MOH) will end its traditional Medicare Advantage prescription drug plans by December 31, 2026, affecting about 80,000 members. The company announced this decision in February 2026, but members were notified in October. Members must choose a new plan by December 7, 2026, to avoid losing coverage and potential penalties. Molina will retain its dual-eligible Medicare business, which generated $5 billion in 2025.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$CNCMed

CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.